Windtree Therapeutics, a biotech firm that recently announced a $700 million BNB treasury strategy, has been delisted from Nasdaq for failing to meet a listing requirement. The BNB Inspired Rally and Subsequent Plunge Biotech company Windtree Therapeutics, which announced a massive $700 million BNB treasury move, has had its stock delisted from Nasdaq for failing […]Crypto News, Altcoin Treasuries, nasdaqRead More

You might also be interested in reading Ethena Labs Partners with UR Global, Brings USDe to Digital Banking.